131 related articles for article (PubMed ID: 36869720)
1. Population pharmacokinetics of unbound and total dolutegravir concentrations in children aged 12 years and older: a PK substudy of the SMILE trial.
Abdalla S; Compagnucci A; Zheng Y; Tréluyer JM; Saidi Y; Ramos JT; Coelho A; Riault Y; Cressey TR; Hirt D;
J Antimicrob Chemother; 2023 Apr; 78(4):1041-1049. PubMed ID: 36869720
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous pharmacokinetic modeling of unbound and total darunavir with ritonavir in adolescents: a substudy of the SMILE trial.
Abdalla S; Compagnucci A; Riault Y; Chan MK; Bamford A; Nolan A; Ramos JT; Constant V; Nguyen T-N; Zheng Y; Tréluyer J-M; Froelicher-Bournaud L; Neveux N; Saidi Y; Cressey TR; Hirt D;
Antimicrob Agents Chemother; 2024 Feb; 68(2):e0100423. PubMed ID: 38092664
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.
Paton NI; Musaazi J; Kityo C; Walimbwa S; Hoppe A; Balyegisawa A; Asienzo J; Kaimal A; Mirembe G; Lugemwa A; Ategeka G; Borok M; Mugerwa H; Siika A; Odongpiny ELA; Castelnuovo B; Kiragga A; Kambugu A;
Lancet HIV; 2022 Jun; 9(6):e381-e393. PubMed ID: 35460601
[TBL] [Abstract][Full Text] [Related]
4. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.
Molina JM; Clotet B; van Lunzen J; Lazzarin A; Cavassini M; Henry K; Kulagin V; Givens N; de Oliveira CF; Brennan C;
Lancet HIV; 2015 Apr; 2(4):e127-36. PubMed ID: 26424673
[TBL] [Abstract][Full Text] [Related]
5. Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
Patel K; Huo Y; Jao J; Powis KM; Williams PL; Kacanek D; Yee LM; Chadwick EG; Shiau S; Jacobson DL; Brummel SS; Sultan-Beyer L; Kahlert CR; Zash R; Seage GR; ;
N Engl J Med; 2022 Sep; 387(9):799-809. PubMed ID: 36053505
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1.
Chandasana H; Singh R; Adkison K; Ait-Khaled M; Pene Dumitrescu T
Antimicrob Agents Chemother; 2024 May; 68(5):e0150423. PubMed ID: 38587380
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
Courlet P; Stader F; Guidi M; Alves Saldanha S; Stoeckle M; Cavassini M; Battegay M; Buclin T; Decosterd LA; Marzolini C;
AIDS; 2020 Jan; 34(1):103-108. PubMed ID: 31490233
[TBL] [Abstract][Full Text] [Related]
8. Adequate plasma levels of dolutegravir in combination with ritonavir-boosted darunavir: a pharmacokinetic subgroup analysis of the DUALIS study.
Weidlich S; Boesecke C; Schneider J; Klinker HHF; Zink A; Balogh A; Wolf E; Bidner H; Spinner CD;
J Antimicrob Chemother; 2020 Oct; 75(10):3082-3084. PubMed ID: 32634214
[No Abstract] [Full Text] [Related]
9. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
Turkova A; Waalewijn H; Chan MK; Bollen PDJ; Bwakura-Dangarembizi MF; Kekitiinwa AR; Cotton MF; Lugemwa A; Variava E; Ahimbisibwe GM; Srirompotong U; Mumbiro V; Amuge P; Zuidewind P; Ali S; Kityo CM; Archary M; Ferrand RA; Violari A; Gibb DM; Burger DM; Ford D; Colbers A;
Lancet HIV; 2022 Sep; 9(9):e627-e637. PubMed ID: 35868341
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Pregnancy on the Pharmacokinetics of Total and Unbound Dolutegravir and Its Main Metabolite in Women Living With Human Immunodeficiency Virus.
Bollen P; Freriksen J; Konopnicki D; Weizsäcker K; Hidalgo Tenorio C; Moltó J; Taylor G; Alba-Alejandre I; van Crevel R; Colbers A; Burger D;
Clin Infect Dis; 2021 Jan; 72(1):121-127. PubMed ID: 32103260
[TBL] [Abstract][Full Text] [Related]
11. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
Bollen PDJ; Moore CL; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Parker A; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Hakim JG; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM;
Lancet HIV; 2020 Aug; 7(8):e533-e544. PubMed ID: 32763217
[TBL] [Abstract][Full Text] [Related]
12. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.
Clotet B; Feinberg J; van Lunzen J; Khuong-Josses MA; Antinori A; Dumitru I; Pokrovskiy V; Fehr J; Ortiz R; Saag M; Harris J; Brennan C; Fujiwara T; Min S;
Lancet; 2014 Jun; 383(9936):2222-31. PubMed ID: 24698485
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.
Rojas J; de Lazzari E; Negredo E; Domingo P; Tiraboschi J; Ribera E; Abdulghani N; Puig J; Mateo MG; Podzamczer D; Gutierrez MM; Paredes R; Clotet B; Gatell JM; Blanco JL; Martínez E;
Lancet HIV; 2021 Aug; 8(8):e463-e473. PubMed ID: 34358497
[TBL] [Abstract][Full Text] [Related]
14. Different effects of the companion antiretroviral drugs on dolutegravir trough concentrations.
Cattaneo D; Pagano S; Colombo ML; Giacomelli A; Gori A; Gervasoni C
AIDS; 2024 May; 38(6):847-851. PubMed ID: 38227571
[TBL] [Abstract][Full Text] [Related]
15. Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial).
Charpentier C; Peytavin G; Raffi F; Burdet C; Landman R; Lê MP; Katlama C; Collin G; Benalycherif A; Cabie A; Mentré F; Yazdanpanah Y; Descamps D; Joly V
J Antimicrob Chemother; 2020 Jun; 75(6):1611-1617. PubMed ID: 32091102
[TBL] [Abstract][Full Text] [Related]
16. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
[TBL] [Abstract][Full Text] [Related]
17. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents.
Chandasana H; Thapar M; Hayes S; Baker M; Gibb DM; Turkova A; Ford D; Ruel T; Wiznia A; Fairlie L; Bwakura-Dangarembizi M; Mujuru H; Alvero C; Farhad M; Hazra R; Townley E; Buchanan A; Bollen P; Waalewijn H; Colbers A; Burger D; Acosta EP; Singh R;
Clin Pharmacokinet; 2023 Oct; 62(10):1445-1459. PubMed ID: 37603217
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of Single-Dose Versus Double-Dose Dolutegravir After Switching From a Failing Efavirenz-Based Regimen.
Griesel R; Banda CG; Zhao Y; Omar Z; Wiesner L; Meintjes G; Sinxadi P; Maartens G
J Acquir Immune Defic Syndr; 2024 May; 96(1):85-91. PubMed ID: 38372621
[TBL] [Abstract][Full Text] [Related]
20. Darunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patients.
Curran A; Martí R; López RM; Pérez M; Crespo M; Melià MJ; Navarro J; Burgos J; Falcó V; Ocaña I; Ribera E
Antimicrob Agents Chemother; 2015 Nov; 59(11):6782-90. PubMed ID: 26282411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
